| |
Newsroom /
Health and Fitness
/
Health and Fitness
/
Autistic Disorder - Pipeline Assessment and Market Forecasts to 2017
Autistic Disorder - Pipeline Assessment and Market Forecasts to 2017
The Autistic Disorder Market is Forecast to Show Increased Growth until 2016
Hyderabad,
AP,
India
(prbd.net)
21/10/2010
GlobalData has estimated the global autistic disorder therapeutics market to be valued at $331m in 2009. It is expected to grow to $765m with a compound annual growth rate (CAGR) of 11.05% by 2017. This growth is primarily attributed to the high increase in prevalence and also the rapid increase in public awareness about the condition. There is a high unmet need which is largely driven by the availability of only a few approved drugs like Abilify and Risperidone that are moderately successful in terms of safety and efficacy profile
The prevalence rate for autistic disorder globally was identified at 0.60% and this accounted for approximately 4.3 million people. Between 2009 and 2017 it is expected to increase from 4.3 million to seven million. Autistic disorder is commonly diagnosed between the ages of one and eight years. A significant increase in autistic disorder incidence has occurred over the past 10 years, especially in the new born population. Hence it is clear that the number of autistic spectrum disorder (ASD) patients seeking treatment in the next five to 10 years will result in an increased usage of therapeutics drugs which in turn will drive the ASD therapeutics market.
For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Autistic-Disorder-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
The global autistic disorder market is dependent on only two drugs Risperidone and Abilify approved by the US Food and Drug Administration (FDA). Most of patients are prescribed anti-depressant or anti-psychotic drugs to treat the symptoms related to autistic disorder. The patent expiry of marketed products such as Risperidone by 2009 allowed the entry of generic products at cheaper prices reducing the market growth as well as the market size.
The unmet need for autistic disorder therapeutics is estimated to be approximately $142m. Currently there is a significant market group that is likely to switch to new products with better efficacy and, in particular, safety. The most common side effects observed after using Abilify are akathisia, restlessness, insomnia, constipation, fatigue and blurred vision. As presented above, this unmet need is approximately 43% of the total market, which is valued at $331m. Therefore, the unmet need within the autistic disorder therapeutics market is estimated to be at least $142m in 2009. Based on our forecasts, the unmet need is likely to grow to at the same rate by 2017. There is unmet need in terms of safety for which technologically innovative products will be required for value capture. The pipeline has limited emerging therapies that are likely to increase the growth of the present market.
GlobalData, the industry analysis specialist’s new report, “Autistic Disorder - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global autism market. The report identifies the key trends shaping and driving the global autism market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global autism sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Autistic-Disorder-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|